Body Rejuvenation - Prolax
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Falls dieses Produkt in Frankreich verkauft würde
- Conditions légales
Frangula purshiana Cooper: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes ainsi qu'une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. Französische Verordnungen vom 9. Mai 2006 (Nährstoffe), 24. Juni 2014 (Pflanzen) und 26. September 2016 (andere Stoffe), konsolidierte LEGI-Sammlung, abgerufen am 23. Oktober 2026.
- Conditions légales
Rheum officinale Baill.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. Französische Verordnungen vom 9. Mai 2006 (Nährstoffe), 24. Juni 2014 (Pflanzen) und 26. September 2016 (andere Stoffe), konsolidierte LEGI-Sammlung, abgerufen am 23. Oktober 2026.
Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle | Täglich höchstens, Erwachsene |
|---|---|---|
| Bifidobacterium breve Quelle : UB8674 | 0,33 Milliards d'UFC | Nicht berechnet |
| Bifidobacterium breve Quelle : Bifidobacterium breve - Cellule entière | 0,33 Milliards d'UFC | Nicht berechnet |
| Plantago ovata Quelle : Enveloppe | 2.128 mg | Nicht berechnet |
| Bifidobacterium longum subsp. infantis Quelle : Bifidobacterium longum subsp. Infantis - Whole Cell | 0,33 Milliards d'UFC | Nicht berechnet |
| Bifidobacterium longum subsp. infantis Quelle : UB9214 | 0,33 Milliards d'UFC | Nicht berechnet |
| Enzymes pancréatiques Quelle : Sus scrofa - pancréas Stärke : 34.450 Unité d'activité protéase de la USP Protease | 325 mg | Nicht berechnet |
| Enzymes pancréatiques Quelle : Sus scrofa - pancréas Stärke : 7.832,5 Unité d'activité lipase de la USP Triacylglycerol lipase | Nicht angegeben | Nicht berechnet |
| Enzymes pancréatiques Quelle : Sus scrofa - pancréas Stärke : 37.350 unité d¿activité amylase de la USP alpha-Amylase | Nicht angegeben | Nicht berechnet |
| Lacticaseibacillus casei Quelle : UB1499 | 7,7473 Milliards d'UFC | Nicht berechnet |
| Chondrus crispus Quelle : En entier | 210 mg | Nicht berechnet |
| Capsicum annuum Quelle : Capsicum annuum - fruit | 20 mg | Nicht berechnet |
| Chondrus crispus | 20 mg | Nicht berechnet |
| Frangula purshiana Quelle : Frangula purshiana - Écorce âgée | 180 mg | Nicht berechnet |
| Juglans cinerea | 160 mg | Nicht berechnet |
| Rheum officinale Quelle : Rheum officinale - Racine et rhizome | 110 mg | Nicht berechnet |
| Zingiber officinale Quelle : Zingiber officinale - Rhizome | 20 mg | Nicht berechnet |
| Syzygium aromaticum | 53 mg | Nicht berechnet |
| Lacticaseibacillus rhamnosus Quelle : UB5115 | 7,7473 Milliards d'UFC | Nicht berechnet |
| Lactiplantibacillus plantarum Quelle : Lactiplantibacillus Plantarum - Cellule entière | 0,077 Milliards d'UFC | Nicht berechnet |
| Lactiplantibacillus plantarum Quelle : UB2783 | 0,077 Milliards d'UFC | Nicht berechnet |
| Lacticaseibacillus paracasei Quelle : UB1978 | 0,055 Milliards d'UFC | Nicht berechnet |
| Vitamine C Quelle : Acide ascorbique | 6 mg | Nicht berechnet |
| Morella cerifera Quelle : Écorce de racine | 70 mg | Nicht berechnet |
| Hibiscus sabdariffa Quelle : Fleur | 126 mg | Nicht berechnet |
Nicht arzneiliche Inhaltsstoffe
Hypromellose, acide oléique, Trehalose, Feuille de stevia rebaudiana, Fécule de pommes de terre, Alginate de sodium, Phosphate dicalcique, Dioxyde de silice, Acide stéarique, Eau d'ammoniaque, Triglycérides à chaîne moyenne, Stéarate de magnésium, Eau purifiée, Extrait de soie de maïs, Croscarmellose de sodium, Xylooligosaccharides, Ethylcellulose
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes | minimum : 19 ans | Non précisée | Non précisée |
In Kanada zugelassene Verwendungen
Acidophilus Ultra DAILY CARE III: Source of probiotics. Acidophilus Ultra DAILY CARE III: Helps support intestinal/gastrointestinal health. Acidophilus Ultra DAILY CARE III: Could promote a favorable gut flora. Prolax: Cascara sagrada is traditionally used in herbal medicine as a stimulant laxative for short term relief of occasional constipation. Prolax: Used in herbal medicine to promote bowel movement by direct action on the large intestine. Ultra Fibre Plantago: Psyllium is used in herbal medicine as a bulk-forming laxative and to promote bowel movements by increasing bulk volume and water content. Ultra Fibre Plantago: Psyllium provides gentle relief of constipation and/or irregularity. Rosemary and Clove are Traditionally used in Herbal Medicine as a carminative for the relief of digestive complaints such as flatulence, or abdominal distention. Pancreatin: Digestive aid. Pancreatin: Helps to decrease bloating after high caloric, high fat meals.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Cautions and Warnings : Do not follow this program during pregnancy or if you are breastfeeding or have any form of inflammatory bowel disease, such as, Crohn¿s disease, regional ileitis, or ulcerative colitis. Should you experience intense discomfort at any time, discontinue the program immediately. The Body Rejuvenation Kit is a nutritional supplement, not a replacement for proper medical attention. This program is not intended as a treatment for any disease or condition. Consult a licensed health care practitioner of your choice if you need direction on any health care problem. For Prolax: Consult a health care practitioner if symptoms persist or worsen. For Prolax: Consult a health care practitioner prior to use if you are taking cardiac medications such as cardiac glycosides or antiarrhythmic medications, thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance. For Prolax: Consult a health care practitioner prior to use if you have a kidney disorder, faecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever. For Prolax: Reduce dose or stop use if you experience abdominal pain, cramps, spasms and/or diarrhoea. For Prolax: Call a Poison Control Center immediately if overdose or accidental ingestion occurs. For Prolax: Keep out of the reach of children. For Acidophilus: If you have fever, vomiting, bloody diarrhoea or severe abdominal pain, consult a health care practitioner prior to use. For Acidophilus: Stop use and consult a health care practitioner if symptoms of digestive upset (e.g. diarrhea) occur, worsen and/or persists beyond 3 days. For Ultra Fibre Plantago: Consult a health care practitioner if symptoms worsen of if laxative effect does not occur within 7 days. For Ultra Fibre Plantago: Consult a health care practitioner if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking the product. For Ultra Fibre Plantago: Consult a health care practitioner prior to use if you are taking medications which inhibit peristaltic movement (e.g. opoids, loperamide), or if you have symptoms such as abdominal pain, nausea, vomiting or fever (as these could be signs of abnormal constrictions of the gastrointestinal tract, disease of the esophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, inflamed bowel or appendicitis). For Ultra Fibre Plantago: Do not exceed the recommended dosage. For Ultra Fibre Plantago: Consult a health care practitioner prior to use if liver function is impaired or if taking acetaminophen or anticoagulants. For Ultra Fibre Plantago: Not for prolonged use in high doses except under supervision of a qualified health care practitioner. For Ultra Fibre Plantago: Consult a health care practitioner prior to use if you have stomach ulcers or inflammation. For Springlife: Stop use and seek medical attention immediately if you experience dizziness, confusion, muscle weakness or pain, abnormal heartbeat and/or difficulty breathing. For Springlife: If you have profuse mucous, consult a health care practitioner prior to use. For Pancreatin: Consult a health care practitioner if symptoms persist or worsen. For Pancreatin: Consult a health care practitioner prior to use if you are pregnant or breastfeeding. For Pancreatin: Consult a health care practitioner prior to use if you have diabetes, pancreatitis, pancreatic exocrine insufficiency or cystic fibrosis. For Pancreatin: Storage conditions: Store in a tightly closed, light-resistant container in a cool, dry place.
Originaltext auf Englisch.
Contra-Indications : For Prolax: Do not use this product if you are pregnant or breastfeeding. For Prolax: Do not use this product if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes or diarrhoea. For Prolax: Do not use if you have hypokalemia, high blood pressure, or a kidney or cardiovascular disorder. For Prolax: Do not use if you have arthritis. For Prolax: Contraindicated in those with a weak stomach and those who do not have constipation. For Acidophilus Ultra: Do not use this product if you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment). For Ultra Fibre Plantago: Do not use if you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product. For Ultra Fibre Plantago: Do not use if you have diabetes mellitus in which blood sugars are difficult to regulate. For Ultra Fibre Plantago: Do not use if you have difficulty swallowing. For Ultra Fibre Plantago: Do not use if you are pregnant or breastfeeding or undergoing corticosteroid treatment. For Ultra Fibre Plantago: Do not use if you suffer from febrile disorder. For Ultra Fibre Plantago: Do not use this product if you are taking thiazide diuretics, cardiac glycosides, corticosteroids, stimulate laxatives or other medications which may aggravate electrolyte imbalance. For Ultra Fibre Plantago: Do not use if you have diabetes, high blood pressure, hypokalemia, liver, heart or kidney disorders. For Springlife: Do not take if you are pregnant or breastfeeding. For Springlife: Do not take if you have been diagnosed with a liver disorder or if liver function is impaired; if you are taking acetaminophen or anticoagulants; if you have a fever and/or suffer from a febrile disorder. For Springlife: If you have heart disease, high or low blood pressure, kidney or liver disorder, diabetes or edema (swelling of hands, face and feet) or are taking products containing diuretics, do not use. For Pancreatin: Do not use if you are sensitive to pancreatic enzymes. For Pancreatin: Do not use if you are sensitive to pork proteins.
Originaltext auf Englisch.
Known Adverse Reactions : For Prolax: Stop use if hypersensitivity/allergy occurs. For Prolax: With chronic use or abuse, disturbances of electrolyte balance, especially potassium deficiency, albuminuria and hematuria may occur; Rectal bleeding or failure to have a bowel movement after the use of a laxative may indicate a serious condition. For Prolax: May cause cramp-like discomfort of the gastrointestinal tract, which may require a reduction of dosage. For Prolax: The astringent effect of rhubarb may exacerbate, rather than relieve symptoms of constipation. For Ultra Fibre Plantago: Hypersensitivity, such as allergy, has been known to occur following inhaled and/or ingested psyllium, in which case discontinue use. For Ultra Fibre Plantago: May cause temporary gas and/or bloating. For Ultra Fibre Plantago: Consult a health care practitioner in the event of an allergic reaction, nausea, vomiting, or diarrhea. For Springlife: Large doses (many times the recommended dosage) of bayberry may be emetic and cause stomach problems. For Pancreatin: Nausea, vomiting, abdominal pain/epigastric pain and/or heartburn have been known to occur, in which case discontinue use (and consult a health care practitioner).
Originaltext auf Englisch.
Produktdaten
- Andere Namen
- Acidophilus Ultra DAILY CARE III
- Inhaber
- New Roots Herbal Inc.
- NPN oder DIN-HM
- 80115009
- Status
- Aktive Lizenz
- Lizenzdatum
- 23. Dezember 2021
- Überarbeitungsdatum
- Nicht angegeben
- Form
- Kit
- Verabreichungsweg
- Orale
- Art des Antrags
- Générale (non traditionelle)
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 80115009
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Offizielle Warnhinweise (Health Canada)
Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:
- Capsicum annuum
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
CAYENNE - CAPSICUM ANNUUM Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Von Health Canada zitierte Quellen (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Von Health Canada zitierte Quellen (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Von Health Canada zitierte Quellen (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Anwendungsbedingung: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografie von Health Canada vom 27. März 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
For external use only (US FDA 2023).
Von Health Canada zitierte Quellen (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Von Health Canada zitierte Quellen (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Von Health Canada zitierte Quellen (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Von Health Canada zitierte Quellen (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Bekannte Nebenwirkungen
Anwendungsbedingung: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Von Health Canada zitierte Quellen (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomisierte Studie
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematische Übersicht
- Frangula purshiana
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
CASCARA SAGRADA - FRANGULA PURSHIANA
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2020; Brinker 2010; WHO 2002).
Von Health Canada zitierte Quellen (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2020; Brinker 2010; WHO 2002; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (5)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Gegenanzeigen
Do not use if you are pregnant or breastfeeding (EMA 2020; Brinker 2010; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2020; Brinker 2010; WHO 2002).
Von Health Canada zitierte Quellen (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Bekannte Nebenwirkungen
Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2020; Brinker 2010).
Von Health Canada zitierte Quellen (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- Zingiber officinale
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
GINGER - ZINGIBER OFFICINALE
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.
Das Belegdatum dieser Zutatenliste ist unbekannt.
Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.